TY  - GEN
AU  - López-Gil, Juan Carlos
AU  - García-Silva, Susana
AU  - Ruiz-Cañas, Laura
AU  - Navarro, Diego
AU  - Palencia-Campos, Adrián
AU  - Giráldez-Trujillo, Antonio
AU  - Earl, Julie
AU  - Dorado, Jorge
AU  - Gómez-López, Gonzalo
AU  - Monfort-Vengut, Ana
AU  - Alcalá, Sonia
AU  - Gaida, Matthias M
AU  - García-Mulero, Sandra
AU  - Cabezas-Sáinz, Pablo
AU  - Batres-Ramos, Sandra
AU  - Barreto, Emma
AU  - Sánchez-Tomero, Patricia
AU  - Vallespinós, Mireia
AU  - Ambler, Leah
AU  - Lin, Meng-Lay
AU  - Aicher, Alexandra
AU  - García García de Paredes, Ana
AU  - de la Pinta, Carolina
AU  - Sanjuanbenito, Alfonso
AU  - Ruz-Caracuel, Ignacio
AU  - Rodríguez-Garrote, Mercedes
AU  - Guerra, Carmen
AU  - Carrato, Alfredo
AU  - de Cárcer, Guillermo
AU  - Sánchez, Laura
AU  - Nombela-Arrieta, César
AU  - Espinet, Elisa
AU  - Sanchez-Arevalo Lobo, Víctor Javier
AU  - Heeschen, Christopher
AU  - Sainz, Bruno
PY  - 2024
DO  - 10.1136/gutjnl-2023-330995
UR  - https://hdl.handle.net/20.500.12105/23079
AB  - OBJECTIVE: Pancreatic ductal adenocarcinoma (PDAC) has limited therapeutic options, particularly with immune checkpoint inhibitors. Highly chemoresistant 'stem-like' cells, known as cancer stem cells (CSCs), are implicated in PDAC aggressiveness....
LA  - eng
PB  - BMJ Publishing Group
KW  - Pancreatic Neoplasms
KW  - Neoplastic Stem Cells
KW  - Carcinoma, Pancreatic Ductal
KW  - Animals
KW  - Mice
KW  - Humans
KW  - Cell Line, Tumor
KW  - Tumor Escape
KW  - Disease Models, Animal
KW  - Immune Evasion
KW  - Tumor Microenvironment
TI  - The Peptidoglycan Recognition Protein 1 confers immune evasive properties on pancreatic cancer stem cells.
TY  - research article
ER  -